Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01827137 · ClinicalTrials.gov registry record · Phase 1
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
A Phase 1 study, sponsored by Sellas Life Sciences Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01827137 is a Phase 1 study that has completed, run by Sellas Life Sciences Group. The registered enrollment target is 20 participants.
The verdict
NCT01827137, a Phase 1 study, has completed, sponsored by Sellas Life Sciences Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess the immune response after vaccination with a peptide vaccine called galinpepimut-S (or GPS) in a type of blood cancer called multiple myeloma. A protein called WT1 is often present in cancerous cells and GPS can train the immune system to recognize and kill the cancerous cells containing WT1. This study will also assess the safety of GPS, effect on disease, and on survival. Participants who has undergone autologous stem cell transplant (ASCT) will receive vaccinations with GPS every 2 weeks for 10 weeks (a total of 6 vaccinations). Vaccinations will start 12 to 22 days after ASCT. In the absence of disease progression and if clinically stable after the first 6 vaccinations, participants may continue to receive six more vaccinations every month. The use of post-ASCT maintenance therapy is allowed starting from 3 months after transplant.
Interventions
- BIOLOGICAL GM-CSF
- DRUG lenalidomide
- BIOLOGICAL Galinpepimut-S
- DRUG bortezomib
- OTHER Montanide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-11-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01827137
The ClinicalTrials.gov registry entry for NCT01827137 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sellas Life Sciences Group, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which GM-CSF is the first listed.
NCT01827137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01827137 about?
NCT01827137 is a clinical study titled "WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation". The purpose of this trial is to assess the immune response after vaccination with a peptide vaccine called galinpepimut-S (or GPS) in a type of blood cancer called multiple myeloma. A protein called WT1 is often present in cancerous cells and GPS can train the immune system to recognize and kill the...
What is the current status of trial NCT01827137?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-04. Estimated completion is 2017-11-06.
What interventions are being tested in trial NCT01827137?
The interventions under investigation include: GM-CSF (BIOLOGICAL), lenalidomide (DRUG), Galinpepimut-S (BIOLOGICAL), bortezomib (DRUG), Montanide (OTHER).
Who is sponsoring clinical trial NCT01827137?
This trial is sponsored by Sellas Life Sciences Group, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.